Cleared Traditional

K051852 - SINGLE AMPLIFIER FOR BOTOX

K051852 is the FDA 510(k) clearance for SINGLE AMPLIFIER FOR BOTOX by Allergan, Inc.. It is a Class 2 Neurology device (product code GWL) cleared through the Traditional 510(k) pathway after a 68-day FDA review.

K051852 · Allergan, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2005
Decision
68d
Days
Class 2
Risk

K051852 is an FDA 510(k) clearance for the SINGLE AMPLIFIER FOR BOTOX. Classified as Amplifier, Physiological Signal (product code GWL), Class II - Special Controls.

Submitted by Allergan, Inc. (Irvine, US). The FDA issued a Cleared decision on September 14, 2005 after a review of 68 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1835 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Allergan, Inc. devices

Submission Details

510(k) Number K051852 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 08, 2005
Decision Date September 14, 2005
Days to Decision 68 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
80d faster than avg
Panel avg: 148d · This submission: 68d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GWL Amplifier, Physiological Signal
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1835
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GWL Amplifier, Physiological Signal

All 17
Devices cleared under the same product code (GWL) and FDA review panel - the closest regulatory comparables to K051852.
Digital NeuroPort Biopotential Signal Processing System
K202174 · Blackrock Microsystems · Feb 2021
8-CH Electroencephalography Amplifier
K201747 · Hipposcreen Neurotech Corp. · Dec 2020
eego amplifiers
K172312 · Eemagine Medical Imaging Solutions GmbH · Mar 2018
MODEL MEB-5304 EVOKED POTENTIAL & ELECTRO. RECORD
K881177 · Nihon Kohden America, Inc. · Sep 1988
MEM-4104 EVOKED RESPONSE/ELECTROMYOGRAPHY RECORDER
K870794 · Nihon Kohden America, Inc. · Sep 1987
NEUROPACK II 5100
K841612 · Nihon Kohden America, Inc. · Jun 1984